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OPEN
SHORT COMMUNICATION
Repeat pneumococcal polysaccharide vaccination does
not impair functional immune responses among
Indigenous Australians
Paul V Licciardi1,2, Edwin Hoe1, Zheng Quan Toh1, Anne Balloch1, Sarah Moberley3, Paula Binks3,
Rachel Marimla1, Amanda Leach3, Sue Skull4,5, Kim Mulholland1,6 and Ross Andrews3
Indigenous Australians experience one of the highest rates of pneumococcal disease globally. In the Northern Territory of
Australia, a unique government-funded vaccination schedule for Indigenous Australian adults comprising multiple lifetime doses
of the pneumococcal polysaccharide vaccine is currently implemented. Despite this programme, rates of pneumococcal
disease do not appear to be declining, with concerns raised over the potential for immune hyporesponse associated with
the use of this vaccine. We undertook a study to examine the immunogenicity and immune function of a single and repeat
pneumococcal polysaccharide vaccination among Indigenous adults compared to non-Indigenous adults. Our results found that
immune function, as measured by opsonophagocytic and memory B-cell responses, were similar between the Indigenous
groups but lower for some serotypes in comparison with the non-Indigenous group. This is the ﬁrst study to document the
immunogenicity following repeat 23-valent pneumococcal polysaccharide vaccine administration among Indigenous
Australian adults, and reinforces the continued need for optimal pneumococcal vaccination programmes among high-risk
populations.
Clinical & Translational Immunology (2017) 6, e158; doi:10.1038/cti.2017.46; published online 6 October 2017
INTRODUCTION
Infections with Streptococcus pneumoniae (the pneumococcus) are
a major cause of morbidity and mortality in children and adults
worldwide. In Australia, Aboriginal and Torres Strait Islander
peoples (hereafter respectfully referred to as ‘Indigenous’) suffer
sixfold higher rates of pneumococcal disease than non-Indigenous
Australians,1 representing one of the highest rates globally. The 23-
valent pneumococcal polysaccharide vaccine (23vPPV) is currently
recommended (and locally funded) for all Indigenous adolescents
and adults in the Northern Territory (NT) of Australia from 15
years of age and is funded through the National Immunisation
Program (NIP) for all adults in Australia aged 65 years or more,
with three lifetime doses recommended (re-vaccination after 5
years and a third dose 10 years after the second, or at 50 years,
whichever is later).2 Despite this, high rates of invasive pneumo-
coccal disease (IPD) have persisted amongst Indigenous adults in
the NT. Immune hyporesponsiveness following repeat 23vPPV
immunisation has been postulated to contribute to the continued
high level of susceptibility to pneumococcal disease in this
population,3 despite having unknown clinical relevance.
RESULTS AND DISCUSSION
We previously described the immune response to 23vPPV among
Indigenous Australians receiving ﬁrst or second dose of 23vPPV and
non-Indigenous Australians receiving a ﬁrst dose, with a signiﬁcantly
lower adequate response among the Indigenous groups.4 While a
second dose of 23vPPV appeared to further reduce serotype-speciﬁc
IgG responses, this was difﬁcult to interpret as second-dose recipients
had higher pre-levels, were older and had more chronic illness
(for example, diabetes).4 This study now further characterises the
23vPPV response, assessing opsonophagocytic responses and B-cell
memory to ﬁve important serotypes (1, 6B, 14, 18C and 19A) before
and after a dose of 23vPPV. The mean time since previous 23vPPV
vaccination among Indigenous second-dose participants was 8 years
and 9 months.
The subset of 60 participants were similar in demographics to those
of the original study population (Supplementary Tables S1 and S2,
online supplement). There was a higher proportion of Indigenous
second-dose recipients with chronic illness (50%) compared to ﬁrst-
dose Indigenous and non-Indigenous groups (20% for both), con-
sistent with the study population. Before 23vPPV, Indigenous ﬁrst-
dose recipients had higher IgG levels for serotypes 14 and 19A, and
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stronger opsonophagocytic responses (opsonophagocytic index; OI)
for serotype 14, compared to non-Indigenous participants (Table 1).
Compared to Indigenous ﬁrst-dose recipients, Indigenous second-dose
recipients had higher baseline IgG levels for serotypes 1, 6B and 14,
and higher OI levels for serotype 14 (Po0.01 for all). The IgG
responses to the remaining vaccine types were published previously.4
The additional analyses undertaken on these participants found no
signiﬁcant differences in post-vaccination serotype-speciﬁc IgG or OI
levels between the ﬁrst- and second-dose Indigenous groups, whereas
non-Indigenous recipients had signiﬁcantly higher IgG and OI levels
for serotype 1 only (Po0.01; Table 1). Analysis of memory B-cell
numbers across all groups and at both time points revealed similar
numbers, except for serotype 6B, which was higher post vaccination in
non-Indigenous compared to Indigenous recipients (Po0.01).
Regardless of baseline, IgG and opsonophagocytic assay (OPA)
responses following 23vPPV increased in all groups for most serotypes
examined (Figure 1 for serotypes 6B and 14; remaining serotypes
shown in Supplementary Figures S1 and 2, online supplement).
However, for serotype 14, Indigenous second-dose recipients
responded with lower OI but not IgG than ﬁrst-dose recipients.
Overall, our data suggest that while Indigenous participants do not
respond as well to selected serotypes in 23vPPV compared to non-
Indigenous participants, repeat 23vPPV immunisation 8–9 years after
the ﬁrst dose among Indigenous participants does not appear to further
reduce vaccine responsiveness. It is possible that immune hyporespon-
siveness may have been missed due to the small numbers or that it may
occur if the doses are given more closely together. Poorer responses to
23vPPV may be due to prior carriage of pneumococci, chronic illness,
environmental factors or ethnicity.5–9 However, the carriage rate was
low in this study (data not shown), similar to a previous report in the
population,10 suggesting other factors may be important in the
response to 23vPPV. There remains controversy over the use of
23vPPV and its potential to induce immune hyporesponsiveness.3
Indeed, studies that have demonstrated hyporesponsiveness following
23vPPV have shown that this is unable to be restored by subsequent
pneumococcal conjugate vaccine (PCV) use.11,12 We have previously
demonstrated this phenomenon in a cohort of Fijian infants given
23vPPV at 12 months of age13 but we also showed that this resolved
after 5 years.14 Although memory B-cell depletion has been suggested
as an explanation for this effect,15 this is not supported by our data. In
older adults, data from several studies have shown inconsistent ﬁndings
in relation to repeated 23vPPV immunisation due to differences in
study design, populations studied or assays used.9,16,17 We have
previously reported that the use of adequate response criteria (as per
the American Academy of Allergy, Asthma and Immunology) reveals
differences in responsiveness that may not be apparent when directly
comparing geometric mean levels of antibody.4 Adapting these criteria
for opsonophagocytic responses may reveal potential differences and is
worth further consideration. The lack of validated response criteria for
OPA or memory B-cell analysis may be one explanation why
hyporesponsiveness was not observed in this study compared to our
previous report based on serotype-speciﬁc IgG response criteria.
Whilst our study is the ﬁrst to compare functional responsiveness to
23vPPV among Indigenous and non-Indigenous Australians and uses
the most up-to-date methods available, we acknowledge the limita-
tions of our design, including the small sample size and the inability to
adjust for confounders such as comorbidities. Furthermore, while the
serotypes selected in this study represent common disease-causing
Table 1 Immune response to 23vPPV among Indigenous Australians receiving a ﬁrst or second dose compared to ﬁrst-dose non-Indigenous
Australians
Indigenous ﬁrst dose (N=20) Indigenous second dose (N=20) Non-Indigenous ﬁrst dose (N=20)
Outcome Pre Post Pre Post Pre Post
Serotype-speciﬁc IgG (μg ml−1)a
1 0.54 (0.37–0.77) 2.45 (1.29–4.63) 1.43** (0.93–2.20) 3.41 (2.03–5.71) 0.38 (0.25–0.56) 9.78** (5.49–17.42)
6B 0.70 (0.45–1.09) 2.85 (1.59–5.13) 1.76** (1.04–2.97) 4.44 (2.53–7.79) 0.44 (0.30–0.64) 2.87 (1.67–4.96)
14 2.43 (1.35–4.37) 12.3 (6.51–23.26) 8.71** (4.83–15.69) 17.98 (10.74–30.09) 0.87* (0.46–17.46) 6.51 (2.91–14.59)
18C 0.80 (0.44–1.46) 3.72 (2.04–6.80) 1.35 (0.84–2.18) 4.05 (2.55–6.44) 0.58 (0.35–0.98) 7.77* (4.94–12.22)
19A 8.11 (5.2–12.64) 10.65 (6.51–17.44) 6.73 (4.46–27.65) 10.16 (7.01–14.71) 2.61*** (1.80–3.78) 6.83 (4.28–10.90)
Opsonophagocytosis (OI)b
1 5 (3–6) 15 (6–39) 5 (4–7) 14 (6–32) 4 (4–4) 240 (88–655)***
6B 16 (8–33) 181 (70–468) 16 (8–33) 202 (70–583) 6 (4–9)* 131 (39–436)
14 13 (5–33) 244 (79–751) 86 (30–251)** 218 (78–610) 9 (5–17) 205 (72–581)
18C 16 (8–35) 83 (30–231) 14 (7–28) 112 (43–290) 6 (4–9)* 191 (67–545)
19A 14 (7–29) 62 (24–160) 22 (9–51) 95 (37–240) 9 (5–18) 108 (41–288)
Memory B cell (×106 PBMC
per ml) c
1 4.1 (1.7) 3.8 (1.3) 3.0 (1.0) 2.6 (0.8) 1.4 (0.9) 4.6 (2.0)
6B 2.7 (0.9) 1.7 (0.5) 2.1 (0.6) 1.2 (0.4) 1.8 (0.6) 4.6 (0.9)**
14 1.9 (0.9) 2.3 (1.0) 2.3 (0.7) 1.3 (0.5) 1.0 (0.3) 3.2 (1.1)
18C 4.3 (1.6) 4.1 (1.7) 3.8 (1.8) 2.1 (0.6) 1.6 (0.5) 2.8 (0.7)
19A 3.5 (1.5) 1.7 (0.6) 4.0 (1.2) 1.7 (0.4) 1.7 (0.5) 2.9 (0.7)
Abbreviations: OI, opsonophagocytic index; PBMC, peripheral blood mononuclear cell; 23vPPV, 23-valent pneumococcal polysaccharide vaccine.
*Po0.05, **Po0.01, ***Po0.001 compared to Indigenous ﬁrst-dose group.
aResults expressed as geometric mean concentration (±95% conﬁdence intervals).
bResults expressed as geometric mean opsonophagocytic index (±95% conﬁdence intervals).
cResults expressed as mean (± s.e.m.). Serotype-speciﬁc IgG responses to the remaining serotypes in 23vPPV have been previously reported.4
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serotypes, it is possible that suboptimal responses to other vaccine
serotypes were missed. Assessment of opsonophagocytosis and B-cell
memory to all 23 serotypes, while challenging, could provide a more
complete understanding of 23vPPV responsiveness.
Implementation of rigorous and optimal pneumococcal vaccination
programmes for high-risk populations is critical to ensure the
continued reduction in IPD in these settings. In consideration of the
13-valent PCV (PCV13) use in adults as part of the NIP in Australia,
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Figure 1 Response to 23vPPV among Indigenous and non-Indigenous Australians. The change in serotype-speciﬁc IgG (μg ml−1) and OI levels after 23vPPV
immunisation is shown for serotypes 6B and 14. Data are log-transformed. The diagonal line represents no change from pre-23vPPV (baseline) levels.
Indigenous Australians given a single dose of 23vPPV are represented by solid circles; Indigenous Australians given a second dose of 23vPPV are represented
by open triangles and non-Indigenous Australians are represented by open circles.
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the use of 23vPPV is currently under review by the Australian
Pharmaceutical Beneﬁts Advisory Committee. PCV13 could therefore
be a strategy to enhance protection in adults in high-risk communities
such as Indigenous Australians.
METHODS
Study population
The details of the study design has been published previously.4 Brieﬂy,
Indigenous Australians were recruited into the study based on whether
they were due to receive a ﬁrst or second dose of 23vPPV, as well as a
non-indigenous Australian control group. A subset of 20 participants
in each of these three groups were analysed in this current study.
Blood samples were collected before and 28 days after a dose of
23vPPV. None of the participants had received PCV previously.
Ethical approval for this study was obtained from the Human
Research Ethics Committee of the NT Department of Health and
the Menzies School of Health Research (06/57), including assessment
by the Aboriginal Ethics Sub-Committee. All investigators were
blinded for the laboratory outcomes.
Pneumococcal serotype-speciﬁc IgG responses
Measurement of serotype-speciﬁc IgG responses to all 23vPPV
serotypes was undertaken using a modiﬁed World Health
Organisation-recommended enzyme-linked immunosorbent assay18
and previously reported. Responses to serotypes 1, 6B, 14, 18C and
19A in this subset are reported in this manuscript.
Opsonophagocytic responses
A multiplexed OPA was used to measure the functional antibody
response for serotypes 6B, 14, 18C and 19A, and a singleplex assay
used for serotype 1 according to a previously published method from
our laboratory.14
Memory B-cell responses
Pneumococcal-speciﬁc memory B-cell numbers were enumerated by
Elispot using an established method published by our laboratory.14
Brieﬂy, peripheral blood mononuclear cells (PBMCs) were isolated
from heparinised whole blood and cultured for 6 days with Staphy-
lococcus aureus Cowan strain—Pansorbin cells (1:5000), 2.5 μg ml− 1
CpG and 83 ng ml− 1 pokeweed mitogen. After 6 days, PBMCs were
collected, washed and plated onto Elispot plates coated with serotypes
1, 6B, 14, 18C and 19A.
Statistical analysis
Serotype-speciﬁc IgG and OIs were presented as geometric mean
concentrations or geometric mean OIs with 95% conﬁdence intervals,
respectively. Log-transformed data were used for statistical analyses of
IgG and OPA data by using paired Student’s t-tests. Means and
standard error for memory B cells were analysed using unpaired
Student’s t-tests. P-values o0.05 were considered signiﬁcant.
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